Additionally, increased levels of CSF MMP-9 were found in individuals exhibiting low Aβ levels, high tau levels, and APOE ε4 positivity, compared to those with negative biomarkers, indicating a significance of MMP-9 in the early pathophysiology of AD, even preceding cognitive decline [36]. This evidence concerns the gene MAPT and Alzheimer disease.